Financial Shenanigans

Financial Shenanigans — Dingdong (Cayman) Limited (DDL)

Verdict: Elevated (48 / 100). Dingdong (Cayman) Limited has no restatement, no admitted misconduct, no auditor resignation, and no SEC enforcement action; Ernst & Young Hua Ming LLP attested that internal controls over financial reporting were effective at December 31, 2025 [1]. The accounting risk is not "this could be a fraud." It is "the headline metrics this management team highlights — fourteen quarters of non-GAAP profit, ten quarters of operating cash inflow, "actual cash owned" net of short-term borrowings — are repeatedly more flattering than the GAAP statements underneath." That gap is widest at three places: the timing of held-for-sale measurement on the Meituan transaction, the multi-year use of bank-funded reversed factoring as a payables substitute, and an SBC-driven non-GAAP "streak" that runs five quarters ahead of GAAP. Reported figures are in RMB; the company reports in RMB and provides convenience USD translations.

Forensic Risk Score (0–100)

▲ 6 Yellow flags

Red flags

CFO / Net Income (3-yr aggregate)

3.42

FCF / Net Income (FY2025)

1.61

Non-GAAP gap (FY25, % of GAAP NI)

33.9%

Q1 FY26 net income lift from ceasing D&A on held-for-sale assets (RMB millions)

138

Reversed-factoring obligations, YE2024 (RMB millions)

636

The two real concerns. First, at December 31, 2025 management concluded the China business did not meet held-for-sale criteria, despite the definitive Meituan share purchase agreement being signed just five weeks later on February 5, 2026 [2]. When Q1 FY2026 reclassified the China business to held-for-sale, ceasing depreciation and amortization on those long-lived assets by itself added RMB138 million (US$20.0 million) to net income for the quarter, and that benefit will recur until the deal closes [3]. Second, the company's headline cash narrative — "actual cash owned, deducting short-term borrowings, increased for the twelfth consecutive quarter" [4] — depends on a self-defined metric. The single offsetting clean test: reverse-factoring obligations are correctly presented under financing activities, not buried in operating cash flow, and the relevant Note 9 disclosure is unusually granular [5].

What would move the grade. A downgrade trigger: any sub-lease assumption change in the FY26 Critical Audit Matter that finally produces an impairment charge on the asset groups EY flagged as carrying "impairment indicators" but for which zero loss has been recognized in any of the past five fiscal years [6][7][8]. An upgrade trigger: a clean Meituan close with cash consideration tracking the signed US$717 million headline price after the US$280M / US$150M net-cash adjustments [2].

1. The Meituan held-for-sale timing question (the highest-impact item)

This is the largest single accounting choice on the page, and management discloses it in plain English — but the disclosure is technical and the dollar impact is recurring until close. On February 5, 2026 Dingdong (Cayman) signed a definitive Share Purchase Agreement with Two Hearts Investments Limited (Meituan, HKEX: 3690) to sell all issued and outstanding shares of Dingdong Fresh Holding Limited ("Dingdong BVI"), which holds substantially all of the China business, for total cash consideration of US$717 million (subject to net-cash, net working-capital and debt-like adjustments) [2]. Management has committed to deploy a "substantial majority" of proceeds to share repurchases and/or dividends [3], and founder Changlin Liang has signed a five-year non-compete covering Greater China To-C fresh grocery e-commerce [9].

The forensic point sits in the timing decision. At December 31, 2025 management concluded the disposal group did not meet ASC 360 held-for-sale criteria (the SPA was signed in 2026, antitrust clearance pending). That choice meant the FY2025 audited balance sheet kept China assets and liabilities as ordinary continuing-ops items, and FY2025 net income absorbed full GAAP depreciation and amortization (RMB97.5 million for the year [10]). Once Q1 FY2026 applied held-for-sale measurement — at the lower of carrying value or fair value less costs to sell — the China-business cost lines stop carrying depreciation/amortization on long-lived assets, and management explicitly quantifies the impact: "an increase of our net income by approximately RMB138 million (US$20.0 million) in the current quarter, and this impact will continue to affect the quarterly net income every period prior to the completion of the Meituan transaction" [3].

No Results

The China business net income exploded from RMB31.9 million to RMB236.9 million year-over-year — a 643.5% jump — and management attributes the bulk of that to the cessation of depreciation on held-for-sale assets [11]. The continuing (overseas) business simultaneously deepened its loss by 199.6% to a RMB71.4 million net loss on RMB139.4 million of revenue [3]. Without the depreciation lift, the consolidated headline result a reader sees on the press release ("net income of RMB165.4 million") would have been roughly RMB27 million — closer to the underlying Q4 FY2025 run-rate [12].

Forensic read. This is not a violation; ASC 360 explicitly allows ceasing depreciation upon held-for-sale classification, and the disclosure is good. The accounting effect is, however, a transient RMB138 million-per-quarter boost masquerading as operational improvement to a reader scanning only the press-release headlines. The underwriting question is whether buy-side models inadvertently extrapolate the post-classification number through 2026 and into a per-share base after the deal closes.

2. Reverse factoring and the "actual cash" cash-flow narrative

The reverse-factoring story is the single most important forensic item to read carefully, because it is simultaneously a clean disclosure (CF1 passes) and the engine behind a quasi-non-GAAP cash framing that management has used for twelve straight quarters.

How the program works

Dingdong (Cayman) extends suppliers a longer trade-payable term by letting them sell receivables on the company into bank-funded reverse-factoring lines. Note 9 of the FY2024 20-F is explicit: "As a result of the above-mentioned reversed factoring arrangements, the payment terms of the Group's original accounts payables were substantially modified and considered extinguished as the nature of the original liability has changed from accounts payables to loan borrowings from the bank, for which the origination of the loans were reported as 'Proceeds from short-term borrowing' within financing activities" [13]. In FY2024 alone the program ran RMB7.02 billion of additions and RMB8.48 billion of settlements through short-term borrowings, producing a year-end balance that fell from RMB2,099 million (FY2023) to RMB636 million (FY2024) [5]. A parallel notes-payable program (bank-issued notes to suppliers, collateralized by time deposits) ran RMB971 million at YE2023 and RMB830 million at YE2024 [14].

The FY2025 20-F MD&A shows short-term borrowings down to RMB871.5 million at YE2025 (from RMB1,606.3 million at YE2024), with interest expenses falling 64.5% from RMB47.3 million to RMB16.8 million as the reverse-factoring book wound down [15][16].

CF1 — the classification test (passes)

The mechanical question — is the company shifting financing inflows into operating cash flow? — comes back clean. Each year the reverse-factoring gross flows are recorded inside Proceeds from / Repayment of short-term borrowings in the financing section: FY2025 saw RMB4,965 million of proceeds and RMB5,700 million of repayments inside financing, leading net financing to -RMB743 million [17]. The change in accounts payable inside operating cash flow is small and clearly disclosed: FY2025 AP increased RMB260 million, FY2024 it increased RMB238 million [10][18]. There is no evidence of supply-chain finance leakage into operating CF.

CF4 / KM2 — the narrative test (yellow)

Management's recurring management-call framing — "after deducting short-term borrowings, our actual cash owned increased to RMB3.14 billion, the tenth consecutive quarter of sustained growth" (Q4 FY2025) [12], "the ninth consecutive quarter of positive cash flow … after deducting short-term borrowings, our actual cash owned increased to RMB3.03 billion" (Q3 FY2025) [19], "after subtracting short-term borrowings, our net equity stood at RMB 2.95 billion" (Q2 FY2025) [20] — is the same metric every quarter, but it is management-defined, not a GAAP cash metric, and it nets a gross financial liability against gross cash. By the Q1 FY2026 call this had become "RMB3,210.6 million, a net increase for the twelfth consecutive quarter" [4]. The streak is real; the framing tacitly concedes that reverse-factoring obligations are economically a trade-payable substitute that legitimately belongs in the leverage assessment.

Two clean readings drop out of the cash-flow table. (i) Cumulative three-year CFO is RMB1,230 million versus cumulative GAAP net income of RMB444 million — a CFO/NI of 2.8x that mostly reflects non-cash operating lease expense (~RMB717 million per year), depreciation, and SBC, not working-capital trickery [10]. (ii) FY2024 CFO of RMB929 million was the strongest year of the series, and the operating-CF walk explicitly identifies AP +RMB238 million, accrued liabilities +RMB95 million, and salary payable +RMB84 million as the dominant working-capital contributors [18]. With AP and accrued liabilities together contributing roughly RMB333 million, roughly one-third of FY2024 CFO came from stretching short-cycle liabilities — a real but non-repeatable working-capital lift. The FY2024 20-F also discloses that AP turnover days dropped from 43.6 in 2023 to 34.9 in 2024 [21] — i.e. the company actually paid suppliers faster, which is the opposite direction one would expect if FY2024 CFO were being inflated by stretching payables. The AP increase is therefore best read as supplier base growth and product-mix shift, not aggressive payment delays.

3. Non-GAAP "streak" versus GAAP (KM1)

The non-GAAP definition is narrow and consistent: "non-GAAP net income excludes share-based compensation expenses" [22]. That definition has not changed across the multi-year corpus. What has drifted is the gap between the two streak counters management cites. By Q1 FY2026 the count was "fourteen consecutive quarters of non-GAAP profitability and nine consecutive quarters of GAAP profitability" [23]. The five-quarter gap is entirely the SBC add-back; nothing else moves between GAAP and non-GAAP.

The reconciliation is a model of clarity — FY2025 SBC of RMB78.4 million bridges GAAP net income of RMB231.7 million to non-GAAP net income of RMB310.1 million [24]. The yellow flag is the framing on the press releases and management calls, where the first metric quoted in the CEO statement is non-GAAP profitability ("Dingdong has maintained profitability under non-GAAP standards for fourteen consecutive quarters" [23]) and the GAAP streak — which is the SEC-preferred metric — is positioned second. Stock-based compensation is a recurring operating cost; treating it as adjustment-worthy "every quarter" is a common practice but is not a one-off. The dollar amount of the SBC add-back has fallen each year (RMB236M → RMB137M → RMB118M → RMB78M), and SBC has been roughly 0.3% of revenue for the past two fiscal years [24] — small relative to peers, which is partly why this scores yellow rather than red.

4. Earnings composition — the role of non-operating income (EM3)

GAAP profitability has been thin and tilted toward non-operating lines. The FY2025 income statement places income from operations at RMB131.7 million on revenue of RMB24,360 million — a 0.5% operating margin [25]. Below the line, RMB125.6 million of interest income and a small RMB407 thousand of other income lift pretax income to RMB240.9 million; the line on the income from operations itself includes RMB145.0 million of "other operating income, net," whose composition is described in MD&A as primarily government subsidies and disposal gains [25].

The forensic point is that interest income plus other operating income equals roughly RMB271 million in FY2025 — more than the RMB232 million GAAP net income. Strip out the non-core lines and the underlying operating engine is, by management's own MD&A description, slightly profitable but not the story the streak counter implies. The fall in interest income — from RMB157.5 million (FY2023) to RMB125.6 million (FY2025) [25] — also tracks the wind-down of short-term investments funded by the IPO cash pile, so this contribution shrinks naturally as the Meituan transaction approaches and capital is returned to shareholders.

5. Capex inflection — capex now outruns depreciation (EM4)

The FY2025 inflection is visible in the cash-flow statement. Capex stepped up from RMB83.3 million in FY2023 to RMB98.2 million in FY2024 to RMB177.8 million in FY2025, while depreciation and amortization stepped down from RMB155.0 million to RMB114.6 million to RMB97.5 million [10][18].

The cross-over in FY2025 — capex roughly 1.8x depreciation — coincides with the announced station-density build-out in the Jiangsu / Zhejiang / Shanghai region and the launch of the "good products" supply-chain investment program. Per management commentary on the Q3 FY2025 call: 40 new frontline fulfilment stations opened year-to-date, including 17 in Q3 [26]. The FY2025 20-F also discloses a fresh RMB12.0 million capital-expenditure commitment for 2026 [17], suggesting the build pace is moderating — but with the China business about to be sold, the relevant capex base for the continuing-ops entity will reset to near zero.

This is not, on this evidence, expense-shifting via capitalization. There is no disclosed change in useful-life assumptions or capitalization thresholds between FY2024 and FY2025 — the property-and-equipment policy table is unchanged — and the depreciation decline is consistent with the asset base aging and FY2022/FY2023's prior, larger PP&E vintage rolling off the books. The flag is yellow on watch: with the China business reclassified to held-for-sale in Q1 FY2026, future PP&E and depreciation analysis for the continuing entity becomes structurally non-comparable, and capex policy on the smaller overseas footprint will need fresh scrutiny.

6. Impairment posture — no charges, indicators present (EM5/EM7)

For five consecutive fiscal years (FY2021 through FY2025), Dingdong (Cayman) has recognized zero impairment losses on its long-lived asset groups, even as Ernst & Young Hua Ming has flagged the impairment assessment as a Critical Audit Matter — language that, in EY's own words, applies specifically to "long-lived asset groups with impairment indicators" [6][7][8]. The auditor's qualifying language is unusually direct: in the FY2024 CAM, EY noted the recoverability test depends on "estimates of the price market participants would pay to sub-lease the operating lease right-of-use assets," with "significant assumptions [that] are forward-looking and include assumptions about economic and market conditions with uncertain future outcomes" [7].

The mechanism EY is testing matters because operating lease ROU assets (RMB1,580 million at YE2025) exceed PP&E (RMB233 million) by a factor of 6.8x [12]; the impairment "pass" therefore largely hinges on management's view of what the Shanghai/Jiangsu/Zhejiang sub-lease market would pay for the company's fulfillment-station leases. The FY2025 CAM language adds an additional softening note — "no impairment losses were recognized for the year ended December 31, 2025" [6] — and notes that the lowest level of independent cash flows is now "each individual geographical region," a refinement from earlier years that disclosed a single national grouping [8].

Why this is a yellow rather than red flag. Once the Meituan transaction completes, the China lease portfolio that drives this CAM moves off the books along with the ROU asset, and the impairment test for the continuing entity collapses to a much smaller overseas footprint. The risk of a deferred write-down therefore resolves through deconsolidation rather than through a P&L impairment charge — which is unusual but not improper. Investors underwriting through the close should still note that the disposal-group conclusion (not HFS at 12/31/25) meant FY2025 carried full GAAP depreciation while Q1 FY2026 stripped it, a pattern that mechanically shifts costs out of the period before the buyer takes economic risk.

7. Working-capital and metric hygiene (KM2)

The KM2 forensic test focuses on whether reported balance-sheet metrics overstate health. Two findings — both yellow, neither severe.

AP turnover days disclosure is consistent across cycles. The 20-F explicitly walks the reader through a multi-year series: 43.0 (FY2022), 43.6 (FY2023), 34.9 (FY2024) days [21]. The FY2025 20-F continues the disclosure with no methodology change. The FY2024 narrative confirms a real acceleration of supplier payments, consistent with the reverse-factoring runoff — i.e. once the bank-funded program contracts, the company must pay suppliers from its own cash, and AP turnover days fall.

The "actual cash owned" metric is not GAAP-defined. Management has used the same definition for twelve straight quarters [4], so the metric itself does not "drift," but the absence of a footnote tying the metric to GAAP cash plus short-term investments minus short-term borrowings does mean retail investors may misread the headline as a "net cash" figure. The Q4 FY2025 press release does provide the reconciliation in prose form (cash + restricted cash + short-term investments + long-term deposits − short-term borrowings) [12], so the disclosure is adequate, but it is presented in the management commentary rather than in a Reg G reconciliation table.

8. Breeding ground — controlled-company governance

The structural risk that amplifies the accounting yellow flags is the governance posture. Dingdong (Cayman) Limited is a "controlled company" under NYSE rules: founder and chairman Changlin Liang beneficially owns 25.2% of total share capital but 80.9% of the aggregate voting power through the dual-class structure (Class B = 10 votes / share) as of December 31, 2025 [27]. The company explicitly elects to rely on the controlled-company exemption from the requirement that "a majority of our board of directors must be independent directors" and on Cayman home-country practices to be exempted from the rules requiring a majority-independent board, a three-member audit committee, an entirely-independent nominating committee, and an entirely-independent compensation committee [28].

The current board has two independent directors out of six (Ed Yiu Cheong Chan, since August 2024; Philip Wai Lap Leung, since June 2021) [29][30]. The audit committee has two members (Leung as chair, Chan), with Leung — a 30-year EY veteran with HKICPA status — designated as the financial expert; for a controlled NYSE listing this is at the minimum acceptable rather than best practice [31]. The compensation committee is chaired by independent director Chan but includes founder Liang himself [31]. The Second Amended & Restated 2020 Share Incentive Plan is administered by the chairman — Mr. Changlin Liang personally — who as plan administrator determines participants, number of options granted, vesting, and "other terms and conditions of each grant" [32].

The CEO transition timing. Liang resigned as CEO on March 4, 2026 — one day before the FY2025 20-F was signed and filed on March 5, 2026 — with director and former CFO Song Wang appointed CEO [29]. Liang retained the chairman role and his 80.9% voting power. The proximity to both the Meituan SPA signing (February 5, 2026 [2]) and the 20-F filing date is timing the page would call out in any other context; here it is part of the disclosed transaction architecture rather than an unexplained departure.

Compensation transparency is at the floor. As a foreign private issuer using aggregate-only disclosure, the FY2024 20-F discloses aggregate cash compensation of US$3.02 million for all executive officers as a group and US$187,500 for all non-executive directors as a group [33] — no per-NEO breakdown. Combined with the founder-controlled share plan administration, the who-gets-what picture is opaque relative to a US domestic 10-K. The Related Party Transactions schedule that appeared as a separate note in the FY2021–FY2023 filings has, since FY2024, been collapsed into a one-line cross-reference back to the compensation section: "See 'Item 6. Directors, Senior Management and Employees—B. Compensation'" [34]. The disappearance is consistent with there being no remaining material related-party transactions (founder loans were repaid pre-IPO), but the absence of an explicit "none" statement is a minor disclosure regression.

Auditor and ICFR. Ernst & Young Hua Ming LLP, the auditor since the IPO, issued an unqualified attestation that ICFR was effective at December 31, 2025; there were no reportable changes in ICFR during FY2025 [1]. Audit-committee policy requires pre-approval of all audit and non-audit services [35]. There is no public restatement, no auditor change, no material weakness, no SEC investigation, and no late filing in the corpus. The only legal matter — a 2022 SDNY securities class action — was voluntarily dismissed by the plaintiff in 2023 [36]. On balance the breeding ground amplifies the accounting flags through ownership concentration, founder-administered SBC, and lean board independence, but does not compound them through auditor or ICFR weakness.

One clean test that builds trust. Despite cumulative GAAP losses of roughly RMB13.2 billion in accumulated deficit at YE2025 [37], the deferred-tax disclosure is conservative: PRC tax-loss carryforwards of RMB11.25 billion are fully offset by a valuation allowance, so management is not booking a deferred-tax asset against the loss history [38]. That is the right call and the cleanest single line in the tax footnote.

9. The 13-shenanigan scorecard

The full taxonomy below. Severity reflects the materiality-weighted forensic risk on current disclosures; "no clear evidence" is stated where the relevant test passes rather than left blank.

No Results

The scorecard above carries citations in the prose sections that introduce each test. The two red flag candidates from the playbook — recording bogus revenue, and shifting financing inflows to operating CF — both come back green here. The genuine concerns concentrate in (i) the held-for-sale timing question on the Meituan disposal (EM7-style timing, in reverse), (ii) the over-reliance of GAAP profit on non-operating income (EM3), (iii) the multi-year zero-impairment posture (EM5), and (iv) the metric-framing patterns around non-GAAP and "actual cash owned" (KM1, KM2).

10. What to underwrite next

The five forensic items worth tracking through the Meituan close and into the first overseas-only annual report.

1. Held-for-sale measurement gain — quantify and exclude. Management has told investors RMB138 million per quarter accrues to net income from the cessation of depreciation on held-for-sale assets [3]. At a quarterly run-rate that is ~RMB550 million annualized. Any FY2026 model that uses Q1 FY2026 net income as a base — especially for per-share repurchase calculations — will overstate the underlying earnings of the continuing entity by that amount. Disconfirming evidence: a Q2 FY2026 disclosure showing the gain has reversed or compressed materially.

2. The Meituan adjustment mechanics — track the gap to the US$717M headline. The SPA price is subject to net cash, net working capital, and debt-like adjustments, with two installments (90% at close, 10% after tax settlement) [2]. The disposal-group balance sheet at March 31, 2026 carried RMB6.37 billion of held-for-sale current assets, RMB1.77 billion of accounts payable, RMB665 million of current operating-lease liabilities, and RMB674 million of short-term borrowings inside the held-for-sale group [39]. Each line moves before the buyer's net-cash adjustment crystallizes. Disconfirming evidence: a closing announcement where realized cash proceeds match the headline US$717 million within working-capital normalization.

3. The continuing-ops earning power — needs a stand-alone read. Q1 FY2026 continuing (overseas) operations posted RMB139 million of revenue and a RMB71 million net loss [11]. Headline overseas revenue grew 195.2% YoY [3], but the loss deepened 199.6%. The entity that will exist after Meituan close is, on this evidence, a sub-scale early-stage operation — the share-buyback / dividend math therefore depends on the deal cash, not on operating earnings. Disconfirming evidence: a meaningful overseas-segment operating margin improvement by Q4 FY2026.

4. Impairment test under the new asset base. FY2026 will be the first year the impairment test is performed on the small overseas footprint rather than the China lease portfolio. Whether the CAM language carries forward, and whether EY identifies new impairment indicators on the overseas asset group, is the cleanest disconfirming signal on the multi-year zero-impairment posture [6].

5. Capital return execution. The 2025 buyback authorization was US$20 million over a 12-month window through March 5, 2026 [35]; FY2025 actually repurchased only US$8.8 million [12]. Management has guided a "substantial majority" of the Meituan proceeds to repurchases and/or dividends [3]; execution against that guidance, with explicit pre-announced amounts, would be the single largest upgrade trigger for the breeding-ground score.

Position-sizing implication

The accounting risk here is best understood as a valuation haircut rather than a thesis breaker. The forensic items do not undermine the fundamental cash that will flow from the Meituan transaction — they shape what the post-close per-share economics actually are. A reasonable underwriting move is to (i) strip the RMB138M/quarter HFS depreciation lift from any per-share earnings used to back into a repurchase price, (ii) value the continuing overseas business at no greater than book through the first two reported quarters as an overseas-only entity, and (iii) reserve a meaningful discount on the headline US$717 million Meituan price for the net-cash/net-working-capital/debt-like adjustments and the tax-deferred 10% installment.

If the Meituan deal closes cleanly and proceeds are returned to shareholders on schedule, the forensic grade resets toward Watch (21–40) within one to two reporting periods, because the largest live forensic items — held-for-sale timing, reverse factoring, the impairment overhang — are deconsolidated with the China business.

References

Generated Jun 19, 2026 10:16 UTC